Astrazeneca (AZN) Accumulated Expenses (2015 - 2025)

Astrazeneca's Accumulated Expenses history runs 11 years deep, the most recent figure standing at $7.3 billion for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 12.3% year-over-year to $7.3 billion; the TTM figure through Dec 2025 stood at $7.3 billion (up 12.3% YoY), while the FY2025 annual figure was $7.3 billion, up 12.3% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $7.3 billion, up from $6.5 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $7.3 billion in Q4 2025, with the low at -$911.0 million in Q1 2021.
• The 5-year median for Accumulated Expenses is $5.9 billion (2021), against an average of $5.0 billion.
• The sharpest annual moves came in 2021 and 2022: Accumulated Expenses surged 44.66% in 2021, then declined 1.73% in 2022.
• Astrazeneca's Accumulated Expenses stood at $5.6 billion in 2021, then fell by 1.73% to $5.6 billion in 2022, then advanced by 10.11% to $6.1 billion in 2023, then gained by 5.74% to $6.5 billion in 2024, then grew by 12.3% to $7.3 billion in 2025.
• Business Quant data shows AZN's Accumulated Expenses at $7.3 billion in Q4 2025, $6.5 billion in Q4 2024, and $6.1 billion in Q4 2023.